The EPSRC CDT in Integrated Catalysis (iCAT) will train students in process-engineering, chemical catalysis, and biological catalysis, connecting these disciplines in a way that will transform the way molecules are made. Traditionally, PhD students are trained in either chemocatalysis (using chemical catalysts such as metal salts) or biocatalysis (using enzymes), but very rarely both, a situation that is no longer tenable given the demands of industry to rapidly produce new products based on chemical synthesis. Graduate engineers and scientists entering the chemical industry now need to have the skills and agility to work across a far broader base of catalysis - iCAT will meet this challenge by training the next generation of interdisciplinary scientists and engineers who are comfortable working in both bio and chemo catalysis regimes, and can exploit their synergies for the discovery and production of molecules essential to society. iCAT features world-leading chemistry and engineering groups advancing the state-of-the-art in bio and chemo catalysis, with an outstanding track record in PhD training. The CDT will be managed by a strong and experienced team with guidance from a distinguished membership of an International Advisory Group. The rich portfolio of interdisciplinary CDT projects will feature blue-sky research blended in with more problem-solving studies across scientific themes such as supramolecular-assisted catalysis using molecular machines, directed evolution and biosynthetic engineering for synthesis, and process integration of chemo and bio-catalysis for sustainable synthesis. The iCAT training structure has been co-developed with industry end-users to create a state-of-the-art training centre at the University of Manchester, equipping PhD students with the skills and industrial experience needed to develop new catalytic processes that meet the stringent standards of a future sustainable chemicals industry in the UK. This chemical industry is world-class and a crucial industrial sector for the UK, providing significant numbers of jobs and creating wealth (currently contributing £15 billion of added value each year to our economy). The industry relies first and foremost on skilled researchers with the ability to design and build, using catalysis, molecules with well-defined properties to produce the drugs, agrochemicals, polymers, speciality chemicals of the future. iCAT will deliver this new breed of scientist / engineer that the UK requires, involving industry in the design and provision of training, and dovetailing with other EPSRC-, University-, and Industry-led initiatives in the research landscape.

Modern society is reliant on chemical synthesis for the discovery, development and generation of a wide range of essential products. These include advanced materials and polymers, bulk fine chemicals and fertilizers, and most importantly products that impact on human health and food security such as medicines, drugs, and agrochemicals. Future developments in these areas are benficial for society as a whole and also for a wide range of UK industries. To date it has been common practice for the chemical industry to recruit synthetic chemists after PhD/postdoctoral training and then augment their synthetic knowledge with specific industrial training. Due to the changing nature of the chemical and pharmaceutical industry it is recognized that synthetic chemists require an early understanding of the major challenges and methodologies of biology and medicine. The concept of our SBM CDT arose from the need to address this skills gap without compromising training in chemical synthesis. We have designed a training programme focused on EPSRC priorities to produce internationally outstanding doctoral scientists fluent in cutting edge synthesis, and its application to problems in biology and medicine. To achieve this, we have formed a genuinely integrated public-private partnership for doctoral training whereby we combine the knowledge and expertise of industrialists into our programme for both training and research. We have forged partnerships with 11 global industrial partners (GSK, UCB, Vertex, Evotec, Eisai, AstraZeneca, Syngenta, Novartis, Takeda, Sumitomo and Pfizer) and a government agency (DSTL), which have offered: (i) financial support (£4.6M cash and £2.4M in-kind); (ii) contributions to taught courses; (iii) research placements; and (iv) management assistance. Our training partners are global leaders in the pharmaceutical and agrochemical industries and are committed to the discovery, development and manufacture of medicines and agrochemicals for the improvement of human health. To fully exploit the opportunities offered by commercial partners, the SBM Centre will adopt an IP-free model to allow completely unfettered exchange of information, know-how and specific expertise between students and supervisors on different projects and across different industrial companies; this would not be possible under existing studentship arrangements. This free exchange of research data and ideas will generate highly trained and well-balanced researchers capable of world-leading research output, and importantly will enable students to benefit from networks between academic and industrial scientists. This will also facilitate interactions between different industrial and government groups, leading to links between pharmaceutical and agrochemical scientists (for example). The one supervisor - one student model, typical of current studentship programmes, is unable to address significant and long-term training and research topics that require a critical mass of multidisciplinary researchers; consequently we propose that substantive research projects will also be cohort-driven. We envisage that this CDT will have a number of training and research foci ('Project Fields') in which synthesis is the unifying core discipline, to enable our public-private partnership to tackle major problems at the chemistry-biology-medicine interface. Our focused research fields are: New Synthetic Methods, 3D Templates for "Lead-Like" Compounds, Functional Probes for Epigenetics, Next Generation Anti-Infectives, Natural Product Chemistry and Tools for Neuroscience. This doctoral training programme will employ a uniquely integrated academic-industrial training model, producing graduates capable of addressing major challenges in the pharmaceutical/agrochemical industries who will ultimately make a major impact on UK science.